Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection.

Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42

Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med (2004) 4.37

Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection. J Virol (2004) 4.20

HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med (2006) 4.19

CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med (2004) 3.78

Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection. J Exp Med (2001) 3.44

Rapid reversion of sequence polymorphisms dominates early human immunodeficiency virus type 1 evolution. J Virol (2006) 2.70

Recognition of a defined region within p24 gag by CD8+ T cells during primary human immunodeficiency virus type 1 infection in individuals expressing protective HLA class I alleles. J Virol (2007) 2.32

Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. J Exp Med (2000) 2.31

Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities. J Virol (2002) 2.03

Portable flanking sequences modulate CTL epitope processing. J Clin Invest (2007) 1.72

Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells after early HIV-1 infection. J Virol (2007) 1.61

Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV. Immunol Rev (2011) 1.44

Long-lived memory T lymphocyte responses after hantavirus infection. J Exp Med (2002) 1.34

Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape. PLoS One (2007) 1.30

Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol (2005) 1.28

Fluctuations of functionally distinct CD8+ T-cell clonotypes demonstrate flexibility of the HIV-specific TCR repertoire. Blood (2005) 1.28

Frequencies of ex vivo-activated human immunodeficiency virus type 1-specific gamma-interferon-producing CD8+ T cells in infected children correlate positively with plasma viral load. J Virol (2002) 1.23

Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes. Proc Natl Acad Sci U S A (2004) 1.22

Human immunodeficiency virus mutations during the first month of infection are preferentially found in known cytotoxic T-lymphocyte epitopes. J Virol (2005) 1.21

The T-cell response to HIV. Cold Spring Harb Perspect Med (2012) 1.20

The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design. J Virol (2005) 1.19

Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1-associated neurodegeneration. J Immunol (2009) 1.14

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol (2000) 1.14

Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity (2015) 1.09

The functional CD8 T cell response to HIV becomes type-specific in progressive disease. J Clin Invest (2002) 1.09

HIV-1 binding to CD4 on CD4+CD25+ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression. Int Immunol (2009) 1.05

Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef. Proc Natl Acad Sci U S A (2003) 1.04

Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood (2012) 1.03

Abundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time. PLoS One (2008) 1.01

Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope. J Immunol (2007) 1.01

Optimizing peptide matrices for identifying T-cell antigens. Cytometry A (2008) 1.00

Study of antigen-processing steps reveals preferences explaining differential biological outcomes of two HLA-A2-restricted immunodominant epitopes from human immunodeficiency virus type 1. J Virol (2002) 0.97

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol (2003) 0.97

The Significance of Interferon-γ in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front Immunol (2014) 0.94

Cross-reactivity between HLA-A2-restricted FLU-M1:58-66 and HIV p17 GAG:77-85 epitopes in HIV-infected and uninfected individuals. J Transl Med (2003) 0.91

Identification of human immunodeficiency virus-1 specific CD8+ and CD4+ T cell responses in perinatally-infected infants and their mothers. AIDS (2009) 0.89

Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from Gag to Pol. J Virol (2007) 0.86

A high viral burden predicts the loss of CD8 T-cell responses specific for subdominant gag epitopes during chronic human immunodeficiency virus infection. J Virol (2007) 0.86

Evidence for predilection of macrophage infiltration patterns in the deeper midline and mesial temporal structures of the brain uniquely in patients with HIV-associated dementia. BMC Infect Dis (2009) 0.86

Changes in function of HIV-specific T-cell responses with increasing time from infection. Viral Immunol (2010) 0.85

HIV-specific T-cell responses detected in the genital tract of chronically HIV-infected women are largely monofunctional. Immunology (2013) 0.84

Human immunodeficiency virus type 1 specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant (CRF07_BC). Retrovirology (2007) 0.81

Influence of dominant HIV-1 epitopes on HLA-A3/peptide complex formation. Proc Natl Acad Sci U S A (2006) 0.78

Dynamic correlation between CTL response and viral load in primary human immunodeficiency virus-1 infected Koreans. Virol J (2010) 0.78

Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption. J Immune Based Ther Vaccines (2006) 0.77

Influence of host resistance on viral adaptation: hepatitis C virus as a case study. Infect Drug Resist (2015) 0.75

Modulating DNA methylation in activated CD8+ T cells inhibits regulatory T cell-induced binding of Foxp3 to the CD8+ T Cell IL-2 promoter. J Immunol (2014) 0.75

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96

Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science (1999) 21.24

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (1997) 15.09

Viral immune evasion due to persistence of activated T cells without effector function. J Exp Med (1998) 14.39

Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05

Reciprocal control of T helper cell and dendritic cell differentiation. Science (1999) 7.28

Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med (1996) 7.08

HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature (1998) 6.94

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med (1995) 6.90

Analysis of a successful immune response against hepatitis C virus. Immunity (1999) 6.31

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med (1999) 6.09

Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med (1997) 5.72

Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med (1998) 5.33

Acute human immunodeficiency virus type 1 infection. N Engl J Med (1998) 5.04

The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med (1998) 4.80

Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol (1999) 3.79

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol (1999) 3.54

A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol (1999) 3.36

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol (1999) 3.22

Emergence of CTL coincides with clearance of virus during primary simian immunodeficiency virus infection in rhesus monkeys. J Immunol (1999) 3.17

Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol Today (1996) 3.01

Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J Immunol (1999) 2.89

Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med (1997) 2.76

Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol (1999) 2.72

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest (1999) 2.42

CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest (1991) 2.40

Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med (1997) 2.38

The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis (1999) 2.27

The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A (1997) 2.24

Lack of strong immune selection pressure by the immunodominant, HLA-A*0201-restricted cytotoxic T lymphocyte response in chronic human immunodeficiency virus-1 infection. J Clin Invest (1998) 2.15

An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol (1993) 1.89

Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med (1996) 1.85

Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. J Virol (1999) 1.62

Downregulation of CD28 surface antigen on CD4+ and CD8+ T lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr (1994) 1.57

Depletion in blood CD11c-positive dendritic cells from HIV-infected patients. AIDS (1999) 1.47

Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys. J Virol (1999) 1.43

Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy. J Infect Dis (1998) 1.39

Ex vivo analysis of cytotoxic T lymphocytes to measles antigens during infection and after vaccination in Gambian children. J Clin Invest (1998) 1.38

Predominant involvement of CD8+CD28- lymphocytes in human immunodeficiency virus-specific cytotoxic activity. J Virol (1996) 1.35

Peptide binding to empty HLA-B27 molecules of viable human cells. Nature (1991) 1.16

Persistent HIV-1-specific CTL clonal expansion despite high viral burden post in utero HIV-1 infection. J Immunol (1999) 1.11

Virologic and immunologic events in primary HIV infection. Springer Semin Immunopathol (1997) 0.99

Antigen-specific expansion of cytotoxic T lymphocytes in acute measles virus infection. J Virol (1999) 0.97

Altered ex vivo balance between CD28+ and CD28- cells within HIV-specific CD8+ T cells of HIV-seropositive patients. Eur J Immunol (1999) 0.90

Different patterns of HIV-1-specific cytotoxic T-lymphocyte activity after primary infection. AIDS (1995) 0.89

Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science (1983) 43.61

Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science (1984) 10.38

The UCSC Genome Browser Database: update 2009. Nucleic Acids Res (2008) 10.31

Isolation of a new human retrovirus from West African patients with AIDS. Science (1986) 7.97

Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med (1996) 4.44

Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet (1999) 4.20

6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Côte d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mère-Enfant. Lancet (1999) 4.11

A prospective study of infants born to women seropositive for human immunodeficiency virus type 1. HIV Infection in Newborns French Collaborative Study Group. N Engl J Med (1989) 3.98

Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med (2000) 3.95

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet (1999) 3.16

Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol (1996) 3.05

Broad, intense anti-human immunodeficiency virus (HIV) ex vivo CD8(+) responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J Virol (1999) 2.72

Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA (2001) 2.63

Retrospective seroepidemiology of AIDS virus infection in Nairobi populations. J Infect Dis (1987) 2.63

Immunological self, nonself discrimination. Science (1987) 2.59

Detection of IgG antibodies to lymphadenopathy-associated virus in patients with AIDS or lymphadenopathy syndrome. Lancet (1984) 2.56

Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J Exp Med (1994) 2.50

Evaluation of clinical case definitions of influenza: detailed investigation of patients during the 1995-1996 epidemic in France. Clin Infect Dis (1999) 2.49

Detection of HIV1 DNA in infants and children by means of the polymerase chain reaction. Lancet (1988) 2.43

Detection of hepatitis C virus in the semen of infected men. Lancet (2000) 2.42

Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science (1992) 2.41

Interaction of peptide antigens and class II major histocompatibility complex antigens. Nature (1987) 2.34

Isolation of new lymphotropic retrovirus from two siblings with haemophilia B, one with AIDS. Lancet (1984) 2.32

Longitudinal study of 94 symptomatic infants with perinatally acquired human immunodeficiency virus infection. Evidence for a bimodal expression of clinical and biological symptoms. Am J Dis Child (1990) 2.30

CCR5 chemokine receptor variant in HIV-1 mother-to-child transmission and disease progression in children. French Pediatric HIV Infection Study Group. JAMA (1998) 2.25

Programmed cell death and AIDS: significance of T-cell apoptosis in pathogenic and nonpathogenic primate lentiviral infections. Proc Natl Acad Sci U S A (1994) 2.21

Several groups among human herpesvirus 6 strains can be distinguished by Southern blotting and polymerase chain reaction. J Clin Microbiol (1991) 2.16

Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection. Blood (2001) 2.16

HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet (1997) 2.11

Varicella as a risk factor for cerebral infarction in childhood: a case-control study. Ann Neurol (1999) 2.05

Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med (2001) 2.05

Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection. The SEROCO Study Group. AIDS (2000) 2.04

Perinatal HIV-1 transmission: interaction between zidovudine prophylaxis and mode of delivery in the French Perinatal Cohort. JAMA (1998) 2.01

Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS. Science (1984) 1.95

Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group. JAMA (1996) 1.94

Familial breast cancer: a controlled study of risk perception, psychological morbidity and health beliefs in women attending for genetic counselling. Br J Cancer (1996) 1.93

A mechanism for the impaired IFN-gamma production in C-C chemokine receptor 2 (CCR2) knockout mice: role of CCR2 in linking the innate and adaptive immune responses. J Immunol (2000) 1.92

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Clin Infect Dis (2013) 1.91

Relation of the course of HIV infection in children to the severity of the disease in their mothers at delivery. N Engl J Med (1994) 1.85

The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer (1999) 1.80

Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol (1998) 1.75

Morbidity and mortality in European children vertically infected by HIV-1. The French Pediatric HIV Infection Study Group and European Collaborative Study. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 1.74

The psychological morbidity of breast cancer-related arm swelling. Psychological morbidity of lymphoedema. Cancer (1993) 1.74

Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science (2000) 1.70

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med (1998) 1.68

Depressed primary in vitro antibody response in untreated systemic lupus erythematosus. T helper cell defect and lack of defective suppressor cell function. J Clin Invest (1980) 1.68

HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A (1998) 1.63

Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2000) 1.63

Clinical and biological relevance of hepatocyte apoptosis in alcoholic hepatitis. J Hepatol (2001) 1.62

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis (2012) 1.62

Solid phase cytometry for detection of rare events. Cytometry (1997) 1.61

Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet (1985) 1.60

Pancreatic lesions in AIDS. Lancet (1987) 1.55

Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia. Blood (1993) 1.55

Enhanced alveolar macrophage-mediated antigen-induced T-lymphocyte proliferation in sarcoidosis. J Clin Invest (1985) 1.54

[Sudden crib death. Experience in a referral center 1986-1991]. Arch Fr Pediatr (1993) 1.53

Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes. J Clin Invest (1990) 1.53

In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol (1999) 1.52

Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS (2001) 1.52

Deletions of the Aequorea victoria green fluorescent protein define the minimal domain required for fluorescence. J Biol Chem (1997) 1.51

Isolation of human T-lymphotropic retrovirus (LAV) from Zairian married couple, one with AIDS, one with prodromes. Lancet (1984) 1.51

Lymphadenopathy-associated viral antibody in AIDS. Immune correlations and definition of a carrier state. N Engl J Med (1984) 1.51

Detailed analysis of the genetic evolution of influenza virus during the course of an epidemic. Epidemiol Infect (2005) 1.51

Detection and quantification of HIV-1 in semen: identification of a subpopulation of men at high potential risk of viral sexual transmission. AIDS (1999) 1.51

Hemolysis and schistocytosis in the emergency department: consider pseudothrombotic microangiopathy related to vitamin B12 deficiency. QJM (2013) 1.50

Effect of a low-dose ketamine regimen on pain, mood, cognitive function and memory after major gynaecological surgery: a randomized, double-blind, placebo-controlled trial. Eur J Anaesthesiol (2007) 1.48

Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J Virol (1998) 1.47

High risk of HIV disease progression after infection through a sexual partner with AIDS. AIDS (1996) 1.45

Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest (1990) 1.44

Puncture injuries due to needles removed from intravenous lines: should the source patient routinely be tested for bloodborne infections? Infect Control Hosp Epidemiol (1993) 1.43

Granulocyte-associated immunoglobulins in renal transplant recipients with cytomegalovirus infection. Lancet (1988) 1.43

[Severe respiratory syncytial virus infections. Study of 87 infants hospitalized in an epidemic]. Arch Fr Pediatr (1989) 1.41

Low-dose zidovudine in children with an human immunodeficiency virus type 1 infection acquired in the perinatal period. Pediatrics (1991) 1.41